Granata Bio Corporation (“Granata Bio”), a biopharma company focused on invigorating the $3.6B global infertility medication market, today announced its $15M Series A+ funding round. The round was exclusively supported by existing investors, including Gedeon Richter, CooperSurgical, Amboy Street Ventures, and other strategic investors. Granata has raised over $30 million to date.
